Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas

被引：4
|
作者：
Rodrigues, M. J. [1 ,2 ]
Albiges-Sauvin, L. [2 ,3 ]
Wassermann, J. [2 ,4 ]
Cottu, P. H. [1 ]
机构：
[1] Inst Curie, Dept Med Oncol, Paris, France
[2] AERIO, Paris, France
[3] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Hop Rene Huguenin, Inst Curie, Dept Med Oncol, St Cloud, France
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷 / 11期
关键词：
CANCER;
D O I：
10.1093/annonc/mdr308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2530 / 2530
页数：1
相关论文
共 50 条
  • [41] Could any pT1a,bN0M0 hormone-responsive, invasive breast carcinomas be safely treated without endocrine therapy?
    Perrin, Christophe
    Frenel, Jean-Sebastien
    Edeline, Julien
    Robert, Marie
    Tas, Patrick
    Lefeuvre-Plesse, Claudia
    Gourmelon, Carole
    Le Du, Fanny
    Campone, Mario
    Kerbrat, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series
    Rodrigues, M. J.
    Peron, J.
    Frenel, J. -S.
    Vano, Y. -A.
    Wassermann, J.
    Debled, M.
    Picaud, F.
    Albiges, L.
    Vincent-Salomon, A.
    Cottu, P. H.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 916 - 924
  • [43] Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
    Dhillon, Sohita
    DRUGS, 2014, 74 (06) : 675 - 686
  • [44] First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy
    Rier, Hanah N.
    Levin, Mark-David
    van Rosmalen, Joost
    Bos, Monique M. E. M.
    Drooger, Jan C.
    de Jong, Paul
    Portielje, Johanneke E. A.
    Elsten, Elisabeth M. P.
    ten Tije, Albert-Jan
    Sleijfer, Stefan
    Jager, Agnes
    ONCOLOGIST, 2017, 22 (08): : 901 - 909
  • [45] Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
    Sohita Dhillon
    Drugs, 2014, 74 : 675 - 686
  • [46] Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy
    Alowais, Shuroug A.
    Luk, Samantha O.
    Kim, E. Bridget
    Alsuhebany, Nada
    Zangardi, Mark
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (06) : 992 - 998
  • [47] Hormone-Receptor Expression and Activity of Trastuzumab-Based Therapy in HER2-Positive Advanced Breast Cancer Patients
    Montemurro, F.
    Rossi, V.
    Rocca, M. Cossu
    Martinello, R.
    Verri, E.
    Redana, S.
    Adamoli, L.
    Valabrega, G.
    Sapino, A.
    Aglietta, M.
    Viale, G.
    Goldhirsch, A.
    Nole, F.
    CANCER RESEARCH, 2010, 70
  • [48] Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer From Early Scientific Development to Foundation of Care
    Brufsky, Adam
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (02): : 186 - 195
  • [49] Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer
    Gori, S.
    Montemurro, F.
    Spazzapan, S.
    Metro, G.
    Foglietta, J.
    Bisagni, G.
    Ferzi, A.
    Silva, R. R.
    Gamucci, T.
    Clavarezza, M.
    Stocchi, L.
    Fabi, A.
    Cognetti, F.
    Torrisi, E.
    Crivellari, D.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1436 - +
  • [50] Benefit of adjuvant chemotherapy for T1cN0M0 and selected T1bN0M0 triple-negative breast cancer: a nationwide cancer registry-based study
    Lo, Chiao
    Chang, Dwan-Ying
    Lu, Yen-Shen
    Wang, Ming-Yang
    Tsai, Li-Wei
    Huang, Chiun-Sheng
    Tang, Chao-Hsiun
    Lin, Ching-Hung
    ONCOLOGIST, 2025, 30 (02):
12345